Patient, disease, and transplantation characteristics
. | All patients . | First chronic phase . |
|---|---|---|
| Median age at transplantation, y (range) | 50 (17-65) | 48 (17-64) |
| Male sex, no. (%) | 113 (60.8) | 73 (61.9) |
| Disease duration, median (range) | 13.5 mo (2 mo to 21.3 y) | 11.7 mo (2 mo to 21.3 y) |
| Longer than 1 y to transplantation, no. (%) | 111 (59.7) | 56 (47.9) |
| Recipient CMV IgG+, no. (%) | 105 (56.5) | 69 (59) |
| Status at transplantation, no. (%) | ||
| CP1 | 118 (63.4) | NA |
| CP2 | 26 (14.0) | NA |
| AP | 30 (16.1) | NA |
| BC | 12 (6.5) | NA |
| No. of prior HSCTs, no. (%) | ||
| 0 | 153 (82.3) | 111 (94.1) |
| 1 | 28 (15.1) | 7 (5.9) |
| At least 2 | 5 (2.7) | 0 (0.0) |
| Donor match, no. (%) | ||
| Matched sibling | 113 (60.8) | 70 (59.3) |
| Matched related | 12 (6.5) | 10 (8.5) |
| Mismatched related | 8 (4.3) | 3 (2.5) |
| Matched unrelated | 47 (25.3) | 33 (28) |
| Mismatched unrelated | 5 (2.7) | 2 (1.7) |
| Donor sex match, no. (%) | ||
| Female to male | 52 (28.1) | 36 (30.5) |
| Male to female | 43 (23.2) | 29 (24.6) |
| Other | 90 (48.7) | 53 (44.9) |
| Cell source, no. (%) | ||
| PBSC | 133 (71.5) | 89 (75.4) |
| BM | 53 (28.5) | 29 (24.6) |
| EBMT score, no. (%)*23 | ||
| 1 | 4 (2.2) | 4 (3.4) |
| 2 | 42 (22.8) | 42 (35.9) |
| 3 | 55 (29.9) | 48 (41) |
| 4 | 38 (20.7) | 17 (14.5) |
| 5 | 35 (18.8) | 6 (5.1) |
| 6 | 9 (4.8) | 0 (0.0) |
| 7 | 1 (0.5) | 0 (0.0) |
. | All patients . | First chronic phase . |
|---|---|---|
| Median age at transplantation, y (range) | 50 (17-65) | 48 (17-64) |
| Male sex, no. (%) | 113 (60.8) | 73 (61.9) |
| Disease duration, median (range) | 13.5 mo (2 mo to 21.3 y) | 11.7 mo (2 mo to 21.3 y) |
| Longer than 1 y to transplantation, no. (%) | 111 (59.7) | 56 (47.9) |
| Recipient CMV IgG+, no. (%) | 105 (56.5) | 69 (59) |
| Status at transplantation, no. (%) | ||
| CP1 | 118 (63.4) | NA |
| CP2 | 26 (14.0) | NA |
| AP | 30 (16.1) | NA |
| BC | 12 (6.5) | NA |
| No. of prior HSCTs, no. (%) | ||
| 0 | 153 (82.3) | 111 (94.1) |
| 1 | 28 (15.1) | 7 (5.9) |
| At least 2 | 5 (2.7) | 0 (0.0) |
| Donor match, no. (%) | ||
| Matched sibling | 113 (60.8) | 70 (59.3) |
| Matched related | 12 (6.5) | 10 (8.5) |
| Mismatched related | 8 (4.3) | 3 (2.5) |
| Matched unrelated | 47 (25.3) | 33 (28) |
| Mismatched unrelated | 5 (2.7) | 2 (1.7) |
| Donor sex match, no. (%) | ||
| Female to male | 52 (28.1) | 36 (30.5) |
| Male to female | 43 (23.2) | 29 (24.6) |
| Other | 90 (48.7) | 53 (44.9) |
| Cell source, no. (%) | ||
| PBSC | 133 (71.5) | 89 (75.4) |
| BM | 53 (28.5) | 29 (24.6) |
| EBMT score, no. (%)*23 | ||
| 1 | 4 (2.2) | 4 (3.4) |
| 2 | 42 (22.8) | 42 (35.9) |
| 3 | 55 (29.9) | 48 (41) |
| 4 | 38 (20.7) | 17 (14.5) |
| 5 | 35 (18.8) | 6 (5.1) |
| 6 | 9 (4.8) | 0 (0.0) |
| 7 | 1 (0.5) | 0 (0.0) |
CMV IgG indicates cytomegalovirus immunoglobulin G; NA, not applicable; CP2, second chronic phase; AP, accelerated phase; BC, blast crisis; PBSC, peripheral-blood stem cell; BM, bone marrow.
The EBMT score is a predictive score (0-7) for outcome after transplantation, developed from registry data from conventional transplantations. The score is as follows: donor type, sibling versus unrelated (0-1), disease stage CP, AP, BC (0-2); age younger than 20 years, 20-40 years, older than 40 (0-2); donor-recipient sex match, female to male versus other (1 or 0); time to transplantation less than 1 year versus longer than 1 year (0-1).